Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Christos

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Journal of Radiosurgery and SBRT|January 3, 2014
Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodesBhupesh Parashar, Prabhsimranjot Singh, Paul Christos, et al.
World Neurosurgery|March 13, 2012
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survivalJan-Karl Burkhardt, Howard Riina, Benjamin J Shin, et al.
Clinical Colorectal Cancer|January 7, 2011
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinomaAllyson J Ocean, Blase Polite, Paul Christos, et al.
Obesity (Silver Spring, Md.)|May 28, 2011
Increased PTH and 1.25(OH)(2)D levels associated with increased markers of bone turnover following bariatric surgeryNaina Sinha, Albert Shieh, Emily M Stein, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2009
MDM2 expression and regulation in prostate cancer racial disparityGuimin Wang, Elnaz F Firoz, Amy Rose, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
American Journal of Clinical Oncology|March 31, 2016
Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid CarcinomaHimanshu Nagar, Weisi Yan, Bhupesh Parashar, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 29, 2022
Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York CityCaroline H Siegel, Jacky M Choi, Debra D'Angelo, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Journal of Radiosurgery and SBRT|January 3, 2014
Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodesBhupesh Parashar, Prabhsimranjot Singh, Paul Christos, et al.
World Neurosurgery|March 13, 2012
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survivalJan-Karl Burkhardt, Howard Riina, Benjamin J Shin, et al.
Clinical Colorectal Cancer|January 7, 2011
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinomaAllyson J Ocean, Blase Polite, Paul Christos, et al.
Obesity (Silver Spring, Md.)|May 28, 2011
Increased PTH and 1.25(OH)(2)D levels associated with increased markers of bone turnover following bariatric surgeryNaina Sinha, Albert Shieh, Emily M Stein, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2009
MDM2 expression and regulation in prostate cancer racial disparityGuimin Wang, Elnaz F Firoz, Amy Rose, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
American Journal of Clinical Oncology|March 31, 2016
Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid CarcinomaHimanshu Nagar, Weisi Yan, Bhupesh Parashar, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 29, 2022
Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York CityCaroline H Siegel, Jacky M Choi, Debra D'Angelo, et al.
Pageof 15